Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

Alpha-1 antitrypsin deficiency (AATD), bronchoscopic lung volume reduction (BLVR), COPD, emphysema, endobronchial valves, hyperinflation, interventional pulmonology, lung volume reduction therapy.

The "Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added ...

The North America alpha-1 antitrypsin deficiency market is expected to lead globally due to advanced healthcare infrastructure, high awareness, and significant research investments. The market is ...

Alpha-1 Antitrypsin Deficiency Market Research 2025-2035, Competitive Analysis of Grifols, CSL Behring, Takeda Pharmaceuticals, LFB Biotechnologies, GlaxoSmithKline, AstraZeneca, Merck, Pfizer ...

AIRNA’s lead program has the potential to be a best-in-class therapeutic for alpha-1 antitrypsin deficiency (AATD). AIRNA has headquarters in Cambridge, MA, with research operations in Tübingen ...

Alpha-1-antitrypsin is a so-called protease inhibitor, a type of enzyme inhibitor. It is produced in the liver but exerts its effects in the lungs, where it regulates immune cell activity. This ...

(RTTNews) - Beam Therapeutics Inc. (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...

About Alpha-1 Antitrypsin Deficiency (AATD) AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease.

The AATD program aims to develop a treatment for alpha-1 antitrypsin deficiency using Prime Editing technology. When does Prime Medicine expect to file for clinical trials?